双特异性磷酸酶26通过抑制转化生长因子β激活激酶1改善小鼠非酒精性脂肪性肝病
研究在小鼠中观察双特异性磷酸酶26(Dusp26)对非酒精性脂肪性肝病(NAFLD)的作用;肝细胞特异性Dusp26敲除加重高脂饮食诱导的肝脂肪变、炎症和胰岛素抵抗,而转基因过表达则改善;Dusp26与TAK1结合阻断其磷酸化,调控TAK1-p38/JNK轴。
要点
- 肝细胞特异性Dusp26敲除加重高脂饮食小鼠肝脂肪变、炎症和胰岛素抵抗。
- 肝细胞特异性Dusp26转基因改善高脂饮食诱导的上述代谢紊乱。
- Dusp26与TAK1结合并阻断其磷酸化,调控TAK1-p38/JNK信号轴。
核心结论
- 作者认为Dusp26是一个依赖TAK1的NAFLD治疗靶点。
研究设计与样本
- 研究采用肝细胞特异性Dusp26敲除小鼠和肝细胞特异性Dusp26转基因小鼠,给予高脂饮食或高脂高胆固醇饮食。
主要发现
- 肝脂肪变小鼠和遗传性肥胖(ob/ob)小鼠肝组织中Dusp26表达降低。
- 高脂饮食诱导的肝细胞特异性Dusp26敲除小鼠肝脂肪变、炎症反应和胰岛素抵抗加重,而肝细胞特异性Dusp26转基因小鼠则改善。
- 高脂高胆固醇饮食诱导的Dusp26敲除小鼠肝纤维化程度加重。
- Dusp26与TAK1结合阻断TAK1磷酸化,调控TAK1-p38/c-Jun NH2末端激酶信号轴以减轻肝脂肪变和代谢紊乱。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD), which has a wide global distribution, includes different stages ranging from simple steatosis to nonalcoholic steatohepatitis, advanced fibrosis, and liver cirrhosis according to the degree of severity. Chronic low-grade inflammation, insulin resistance, and lipid accumulation are the leading causes of NAFLD. To date, no effective medicine for NAFLD has been approved by governmental agencies. Our study demonstrated that the expression of dual-specificity phosphatase 26 (Dusp26), a member of the Dusp protein family, was decreased in the liver tissue of mice with hepatic steatosis and genetically obese (ob/ob) mice. In our study, hepatic steatosis, inflammatory responses, and insulin resistance were exacerbated in liver-specific Dusp26-knockout (KO) mice but ameliorated in liver-specific Dusp26-transgenic mice induced by a high-fat diet. In addition, the degree of liver fibrosis was aggravated in high-fat high-cholesterol diet-induced Dusp26-KO mice. We further found that the binding of Dusp26 to transforming growth factor beta-activated kinase 1 (TAK1) to block the phosphorylation of TAK1 regulated the TAK1-p38/c-Jun NH2-terminal kinase signaling axis to alleviate hepatic steatosis and metabolic disturbance. Conclusion: These findings suggest that Dusp26 is a good TAK1-dependent therapeutic target for NAFLD.
引用
- Ye P, Liu J, Xu W, et al. Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression. Hepatology. 2019. PMID: 30582764. doi:10.1002/hep.30485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。